179 related articles for article (PubMed ID: 19894220)
1. Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.
Shapovalov Y; Benavidez D; Zuch D; Eliseev RA
Int J Cancer; 2010 Jul; 127(1):67-76. PubMed ID: 19894220
[TBL] [Abstract][Full Text] [Related]
2. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis.
Xian M; Cao H; Cao J; Shao X; Zhu D; Zhang N; Huang P; Li W; Yang B; Ying M; He Q
Int J Cancer; 2017 Sep; 141(5):1029-1041. PubMed ID: 28524233
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
7. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
8. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF
Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.
Lou Z; Ren T; Peng X; Sun Y; Jiao G; Lu Q; Zhang S; Lu X; Guo W
J Int Med Res; 2013 Oct; 41(5):1505-19. PubMed ID: 23975859
[TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
11. Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.
Eriksson E; Wickström M; Perup LS; Johnsen JI; Eksborg S; Kogner P; Sävendahl L
J Natl Cancer Inst; 2014 Mar; 106(3):djt459. PubMed ID: 24586107
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Conticello C; Adamo L; Giuffrida R; Vicari L; Zeuner A; Eramo A; Anastasi G; Memeo L; Giuffrida D; Iannolo G; Gulisano M; De Maria R
J Clin Endocrinol Metab; 2007 May; 92(5):1938-42. PubMed ID: 17327374
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells.
Nakamura T; Tanaka K; Matsunobu T; Okada T; Nakatani F; Sakimura R; Hanada M; Iwamoto Y
Int J Oncol; 2007 Oct; 31(4):803-11. PubMed ID: 17786311
[TBL] [Abstract][Full Text] [Related]
15. Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib.
Uyama M; Sato MM; Kawanami M; Tamura M
Genes Cells; 2012 Jul; 17(7):548-58. PubMed ID: 22702336
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.
Huang C; Hu X; Wang L; Lü S; Cheng H; Song X; Wang J; Yang J
Cancer Chemother Pharmacol; 2012 Dec; 70(6):801-9. PubMed ID: 22996635
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
Ko BS; Chang TC; Chen CH; Liu CC; Kuo CC; Hsu C; Shen YC; Shen TL; Golubovskaya VM; Chang CC; Shyue SK; Liou JY
Life Sci; 2010 Jan; 86(5-6):199-206. PubMed ID: 20006625
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
Chu S; Alexiadis M; Fuller PJ
Reprod Sci; 2009 Apr; 16(4):397-407. PubMed ID: 19087975
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.
Khan T; Stauffer JK; Williams R; Hixon JA; Salcedo R; Lincoln E; Back TC; Powell D; Lockett S; Arnold AC; Sayers TJ; Wigginton JM
J Immunol; 2006 May; 176(10):6302-12. PubMed ID: 16670342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
